Philip Smith, MD
Ophthalmology · Madison, MSNPI 1942206149
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,552 of the $4,992 with a category attached, or 71.2%. 19 manufacturers reported payments, led by Alcon at 58.2% of the total. Reporting peaked in 2024 at $2,152 and has fallen 70.1% since, to $643 in 2025.
Across 121 payments — averaging $41.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$375
- Novartis$321
- Mallinckrodt Hospital Products Inc.$297
- Bausch & Lomb Americas Inc.$167
- Amgen$158
- plus $771 from 13 others
What the payments were for
- Travel & lodging$1,44029%
- Food & beverage$3,55271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 26 | $2,904 |
| AbbVie(2 entities) | 23 | $375 |
| Novartis | 19 | $321 |
| Mallinckrodt Hospital Products Inc. | 10 | $297 |
| Bausch & Lomb Americas Inc. | 9 | $167 |
| Amgen(2 entities) | 3 | $158 |
| Glaukos Corporation | 1 | $130 |
| Johnson & Johnson Vision Care, Inc. | 6 | $129 |
| Rxsight Inc | 1 | $101 |
| Oyster Point Pharma, Inc. | 4 | $81 |
| Biotissue Holdings Inc. | 4 | $72 |
| ANI Pharmaceuticals, Inc. | 3 | $61 |
| Shire North American Group Inc | 3 | $53 |
| Aerie Pharmaceuticals, Inc. | 3 | $51 |
| Kala Pharmaceuticals, Inc. | 2 | $26 |
| Thea Pharma Inc. | 1 | $20 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$1,734
- Clareon$143
- Precision 7$129
- AcrySof IQ PanOptix$128
- AcrySof$127
- TEPEZZA$112
- ARGOS$107
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$101
How this compares
$4,992 in reported general payments places this provider in the 80th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 54 | $23,749 |
| RestasisCyclosporine | 30 | $23,571 |
| XiidraLifitegrast | 20 | $16,285 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $6,650 |
| Latanoprost | 542 | $5,877 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $5,848 |
| Prednisolone Acetate | 115 | $3,218 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 92 | $1,856 |
| Ketorolac Tromethamine | 111 | $1,464 |
| Brimonidine Tartrate | 145 | $1,372 |
| Ciprofloxacin Hcl | 112 | $1,186 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 118 | $1,126 |
| Dexamethasone Sodium Phosphate | 24 | $859 |
| Dorzolamide Hcl | 37 | $799 |
| Timolol Maleate | 45 | $357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $375 | $53,970104 claims |
| Bausch & Lomb Americas Inc.Xiidra | $167 | $16,28520 claims |
| AlconSimbrinza | $2,904 | $5,84817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Madison
- William AshfordMadison$13K
- Elizabeth MitchellMadison$5K
- Robert BrowningMadison$4K
- Kevin KosekMadison$4K
- Alexander WhittingtonMadison$3K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.